Novartis AG (NYSE:NVS) gapped down prior to trading on Monday . The stock had previously closed at $77.68, but opened at $78.27. Novartis AG shares last traded at $79.38, with a volume of 1,352,900 shares changing hands.

Several research firms have weighed in on NVS. Zacks Investment Research raised shares of Novartis AG from a “hold” rating to a “buy” rating and set a $92.00 price target for the company in a research note on Monday, July 11th. Citigroup Inc. reaffirmed a “neutral” rating on shares of Novartis AG in a research note on Wednesday, May 18th. TheStreet raised shares of Novartis AG from a “hold” rating to a “buy” rating in a research note on Friday, June 24th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Novartis AG in a research note on Thursday, May 26th. Finally, Bank of America Corp. reaffirmed a “hold” rating on shares of Novartis AG in a research note on Tuesday, July 12th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $91.20.

The firm has a 50-day moving average of $81.72 and a 200-day moving average of $77.68. The stock has a market cap of $189.02 billion and a price-to-earnings ratio of 28.34.

Novartis AG (NYSE:NVS) last announced its quarterly earnings results on Tuesday, July 19th. The company reported $1.23 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.18 by $0.05. The firm had revenue of $12.47 billion for the quarter, compared to analysts’ expectations of $12.33 billion. During the same period in the previous year, the company earned $1.25 EPS. On average, equities analysts predict that Novartis AG will post $4.73 EPS for the current year.

Novartis AG is a holding company. The Company specializes in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals, including eye care products. Its portfolio includes medicines, eye care and generic pharmaceuticals. The Company’s segments include Pharmaceuticals, Alcon and Sandoz.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.